262 18 Months Followup After Intra-Articular Administration of Hyalubrix® in 344 Patients With Symptomatic Osteoarthritis of the Hip

High Molecular Weight Hyaluronic Acid (Hyalubrix/HyalOne) for Treating Symptomatic Hip Osteoarthritis

“…Over seven years, no systemic or severe local side effects were ever reported. Some patients experienced pain after injection that lasted from several hours to few days, confirming previous data 49,50,52 . In conclusion, the study showed that HyalOne, while displaying an excellent safety profile, did not lose efficacy over time even after repeated injections over more years.…”

“…One mepivacaine patient suffered from mildly intense pain at the injection site that resolved spontaneously after 36 hours. Results from the prospective study previously mentioned 49 concerning a cohort of hip OA patients treated by HyalOne injections showed that the number of subjects who, at the end of the 18-month follow-up period, had to undergo THR was low (8 patients out of 239, for a THR rate of about 3%). Consistent with indications of the EULAR agenda 3 prompting researchers to assess whether viscosupplementation can slow the progression of osteoarthritis and/or to delay joint replacement, a further study was therefore carried out to compare the recommendations for THR at baseline, provided by a group of independent orthopedists, with the actual rate of THR received by the patients during a cohort 48-month followup 52 .…”

“…The study involved 120 patients that were subjected to 4ml/60 mg intra-articular HyalOne injections every six months and, if needed, to additional injections every three months, and were followed up to 18 months after the first injection. Scores collected were the same used during the previous study 49 ; a statistically significant reduction in algofunctional indexes was observed even at 3 months after the first injection. At 12 months, 80% of the patients achieved a ≥ 30% decrease in symptoms.…”

“…Preliminary results concerning Hyalubrix/HyalOne USguided intra-articular injection for treating Hip OA were provided in 2008 at the OARSI (OsteoArthritis Research Society International) World Congress on Osteoarthritis 49 , describing how 239 adults (271 joints), ambulatory patients suffering from hip OA grade 1 to 3 according to Kellgren and Lawrence, were prospectively recruited and injected using (4 ml / 60 mg) of HyalOne every six months or, if needed because of their clinical conditions, every three months. Patients were then followed-up every three months up to 18 months after the first injection.…”

<p>Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data</p>

“…Our group has extensively studied the effect of HA viscosupplementation in managing symptoms of hip OA, using non-modified HA within the 1.5-2.0 MDa range injected under US guidance. [27][28][29][30][31][32] In a recent prospective, post-market seven-year followup cohort study whose data were collected from the Associazione Nazionale per la Terepia Intra Articolare dell'Anca con Guida Ecografica (ANTIAGE) register, we found that hip OA patients who received non-modified HA injections at least every 6 months showed, at all time points and compared to baseline, a statistically significant improvement of Lequesne index, pain visual analogue scale (VAS), NSAID intake, and global medical and patient assessments. 32 Modifications made to HA to improve its rheology and resorption kinetics may, in principle, modulate the clinical response of patients to IA injection; consequently, the optimal therapeutic protocol for a given HA formulation should be investigated on a case-by-case basis.…”